An interventional study of SING IMT(TM) System, model NG SI IMT 3X in AMD and Age-Related Macular Degeneration, sponsored by VisionCare, Inc.. Active, not recruiting at 13 sites in 7 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Macular Degeneration by VisionCare, Inc. — 2 open to participants now, 3 under way, none of them phase 3. Macular Degeneration · VisionCare, Inc..
Among the 10 studies in Macular Degeneration by VisionCare, Inc., this one is the 4th largest by enrollment, is one of 2 that started in 2022, is one of 9 with no phase, and was the 7th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →2 of the 10 studies in Macular Degeneration by VisionCare, Inc. are open now, in 4 countries. Recruiting first, the newest first:
VisionCare, Inc. · Sites in France, Germany, Italy
Ages 55+
VisionCare, Inc. · Sites in United States
Ages 65+
By country, each count listing its studies:
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2022.
This study's enrollment of 68 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 31 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
VisionCare, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
2 of the studies in Macular Degeneration by VisionCare, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07164378VisionCare, Inc.International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study | 2026-12-30 |
| NCT04796545VisionCare, Inc.Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Macular Degeneration by VisionCare, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD).
Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.
This is an interventional, prospective, multicenter, open label, single group assignment Post-Market Clinical Follow-up (PMCF) study in men and women >=55 years with central vision impairment associated with end-stage AMD.
Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study. Baseline visual acuity of the study subjects will be assessed with a 2.8X external telescope simulator (ETS) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts to determine if they are likely to benefit from receiving the IMT. To be included in the study and to proceed with the surgery, subjects must achieve, using the ETS, at least a one line (5 or more letters) improvement in distance on the ETDRS chart in the eye scheduled for surgery. Subjects not meeting these criteria will be excluded from the study.
If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery.
Postoperatively, the surgeon will complete a usability and satisfaction questionnaire after each implantation procedure.
The patients will undergo ophthalmic evaluations in both eyes at regular intervals for up to 12 months. The subjects will also be required to undergo 6 to 10 additional visits for vision training with a low vision specialist.
Surgical complications, as well as all Adverse Event (AEs) and use of medications will be monitored from baseline to the end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients for whom the planned operative eye has:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will be implanted with the SING IMT System model NG SI IMT 3X.
Device: SING IMT(TM) System, model NG SI IMT 3X
The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
Safety of the SING IMT System, model NG SI IMT 3X, including its delivery system
The percent decrease in endothelial cell density (ECD).
Time frame: 12 months
Incision size needed for device implantation
Incision size will not exceed 8.0 mm (non-inferiority assumption) in 75% of surgeries
Time frame: 12 moths
Surgical complications
AEs and serious adverse events
Time frame: 12 moths
Improvement in near and distance best corrected visual acuity (BCVA) in implanted eyes.
Near and distance BCVA will show an improvement of ≥2 lines in the ETDRS chart in at least 50% (non-inferior to 50%) of the implanted eyes at 12 months post implantation.
Time frame: 12 months
Usability of SING IMT System, including delivery system
Surgeon will complete a usability and satisfaction questionnaire
Time frame: 12 months
Device stability and fixation
Assessed by slit lamp biomicroscopy examination: device tilt and device decentration
Time frame: 12 months
Post-operative anterior chamber depth (ACD)
Anterior Chamber Depth (ACD) evaluated by ultrasound biomicroscopy (UBM), ocular coherence tomography (OCT) or another applicable test method
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for May 2027, 56 months after the start.
Of 133 interventional studies with no phase under Macular Degeneration, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 56 months is above that.
Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → May 2027, on Sep 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VisionCare, Inc.